# Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)

> **NCT00562640** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** therapeutic autologous lymphocytes
- **DRUG:** cyclophosphamide
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00562640
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-16
- **Primary completion:** 2021-08-03
- **Final completion:** 2021-08-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00562640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00562640, "Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00562640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*